Results 91 to 100 of about 575,775 (211)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer

, 2008
Udgivelsesdato: 2008-MayErbB receptors (EGFR (ErbB1), ErbB2, ErbB3, and ErbB4) are important regulators of normal growth and differentiation, and they are involved in the pathogenesis of cancer.
Kirstine Roepstorff, Roepstorff, Kirstine, Bo van Deurs, Lerdrup, Mads, Mads Lerdrup, Lene Grøvdal, Grandal, Michael, Michael Grandal, Grøvdal, Lene, van Deurs, Bo   +9 more
core   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

ERBB RECEPTORS DIMERIZATION DEFINES BREAST CANCERS SUBTYPES AND CLINICAL OUTCOMES: IMPLICATION FOR CANCER THERAPIES

, 2016
Breast cancers are classified into categories according to specific criteria, such as histopathological type, tumour grade and more recently the gene expression signature.
Adriana Albini, Nicoletta Macrì, Mattia Lauriola, D’Uva Gabriele, Massimiliano Bonafè, Valerio Gelfo, Davide D’Urso   +6 more
core   +1 more source

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan

BMC Cancer, 2012
Background Acquired resistance to endocrine therapy in breast cancer is a significant problem with relapse being associated with local and/or regional recurrence and frequent distant metastases.
Hiscox Stephen, Baruha Bedanta, Smith Chris, Bellerby Rebecca, Goddard Lindy, Jordan Nicola, Poghosyan Zaruhi, Nicholson Robert I, Barrett-Lee Peter, Gee Julia   +9 more
doaj   +1 more source

Periodontitis and metabolic dysfunction‐associated steatotic liver disease

Periodontology 2000, EarlyView.
Abstract Objective Periodontitis is a chronic inflammatory disease with systemic effects that extend beyond the oral cavity and contribute to systemic immune and metabolic dysregulation. Chronic liver diseases, particularly metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive phenotypes, have emerged as major global ...
Rafael Scaf de Molon, Erica Dorigatti de Avila, Davi da Silva Barbirato, Mariana Fampa Fogacci, Jamil Awad Shibli, Anton Sculean, Alpdogan Kantarci   +6 more
wiley   +1 more source

ErbB receptors: directing key signaling networks throughout life.

, 2004
The epidermal growth factor (EGF)-related peptides bind the ErbB receptors, inducing the formation of different homo- and heterodimers. Receptor dimerization promotes activation of the intrinsic kinase, leading to phosphorylation of specific tyrosines ...
Holbro T, Hynes NE
core   +1 more source

Maternal obesity during lactation as a hypertensive cardiovascular risk factor in the offspring

Experimental Physiology, EarlyView.
Abstract Maternal obesity is a major public health concern, with growing evidence supporting its role in the developmental programming of cardiometabolic disease. Although prenatal mechanisms have been investigated extensively, the contribution of lactation as a postnatal window of cardiovascular (CV) programming remains insufficiently understood ...
Gabriela Arenas, Cristián A. Amador, Susana Contreras‐Duarte   +2 more
wiley   +1 more source